Evidence map›Paper›PMID 38606196›Full record

ArticleFrontiers in neuroimaging2024

Evaluation of partial volume correction and analysis of longitudinal [

Sandra M Sanabria Bohórquez, Suzanne Baker, Paul T Manser, Matteo Tonietto, Christopher Galli, Kristin R Wildsmith, Yixuan Zou, Geoffrey A Kerchner, Robby Weimer, Edmond Teng

2 registry-linked trialsOpen access · diamondAbstract read
In one paragraph

Article in Frontiers in neuroimaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02640092 phase1completednot on this map

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers

TypeinterventionalSponsorGenentech, Inc.Ran2015 to 2019Enrolled72ConditionsAlzheimer's DiseaseArms[18F]GTP1
NCT03289143 phase2terminatednot on this map

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

TypeinterventionalSponsorGenentech, Inc.Ran2017 to 2021Enrolled457ConditionsAlzheimer's DiseaseArmsSemorinemab, Placebo, [18F]GTP1
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Sandra M Sanabria BohórquezClinical Imaging Group, Genentech, Inc., South San Francisco, CA, United States.
Suzanne BakerClinical Imaging Group, Genentech, Inc., South San Francisco, CA, United States.
Paul T ManserBiostatistics, Genentech, Inc., South San Francisco, CA, United States.
Matteo ToniettoRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Christopher GalliRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kristin R WildsmithBiomarker Development, Genentech, Inc., South San Francisco, CA, United States.
Yixuan ZouData and Statistical Science, Product Development, Hoffmann-La Roche Ltd., Basel, Switzerland.
Geoffrey A KerchnerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Robby WeimerTranslational Imaging, Genentech, Inc., South San Francisco, CA, United States.
Edmond TengEarly Clinical Development, Genentech, Inc., South San Francisco, CA, United States.
Roche (Switzerland) · CHBiomarker Technologies (China) · CNColorado Permanente Medical Group · USElucid Bioimaging · USSunesis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: We evaluated the impact of partial volume correction (PVC) methods on the quantification of longitudinal [ Methods: We applied van Cittert iterative deconvolution (VC), 2-compartment, and 3-compartment, and the geometric transfer matrix plus region-based voxelwise methods to data acquired in an Alzheimer's disease natural history study over 18 months at a single imaging site. We determined the optimal PVC method by comparing the standardized uptake value ratio change (%ΔSUVR) between diagnostic and tau burden-level groups and the longitudinal repeatability derived from the LMEM. The performance of LMEM analysis for calculating %ΔSUVR was evaluated in a natural history study and in a multisite clinical trial of semorinemab in prodromal to mild Alzheimer's disease by comparing results to traditional per-visit estimates. Results: The VC, 2-compartment, and 3-compartment PVC methods had similar performance, whereas region-based voxelwise overcorrected regions with a higher tau burden. The lowest within-subject variability and acceptable group separation scores were observed without PVC. The LMEM-derived %ΔSUVR values were similar to the per-visit estimates with lower variability. Conclusion: The results indicate that the tested PVC methods do not offer a clear advantage or improvement over non-PVC images for the quantification of longitudinal [ Clinical trial registration: NCT02640092 and NCT03289143.

Indexed as

Alzheimer's diseaselinear mixed-effects modelslongitudinal changeneuroimagingtau PET

Identifiers

PMID38606196
PMCPMC11008283
OpenAlexW4393278101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.